| Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs | Sarah de Crescenzo | 06/05/20 | Boston |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID | Sarah de Crescenzo | 04/02/20 | National |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments | Sarah de Crescenzo | 03/25/20 | Boston |
| Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug | Sarah de Crescenzo | 03/11/20 | Seattle |
| New Meds Set to Reshape US CNS and Oncology Markets | Gareth Macdonald | 02/18/20 | National |
| Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup | Frank Vinluan | 02/04/20 | New York |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto | Sarah de Crescenzo | 01/07/20 | San Diego |
| Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs | Frank Vinluan | 12/10/19 | New York |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval | Frank Vinluan | 11/08/19 | New York |
| Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer | Frank Vinluan | 10/21/19 | Boston |
| Plexium Debuts With $28M and a New Take on Protein Degradation Drugs | Sarah de Crescenzo | 10/17/19 | San Diego |
| Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug | Frank Vinluan | 10/15/19 | Boston |
| Gilliland to Step Down as Head of Fred Hutch in 2020 | Jeff Buchanan | 09/17/19 | Seattle |
| Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More | Alex Lash | 08/30/19 | National |
| Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight | Ben Fidler | 08/28/19 | New York |
| Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal | Frank Vinluan | 08/26/19 | New York |
